|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:KAI_Pharmaceuticals
gptkb:Teneobio
KAI Pharmaceuticals (2012)
Onyx Pharmaceuticals (2013)
|
|
gptkbp:advocacy
|
gptkb:Yes
|
|
gptkbp:annual_report
|
gptkb:Yes
|
|
gptkbp:awards
|
gptkb:Fortune_500
gptkb:Diversity_Inc_Top_50
Best Places to Work
World's Most Admired Companies
Top Employers
|
|
gptkbp:biologics
|
gptkb:Yes
|
|
gptkbp:biopharmaceuticals
|
gptkb:Yes
|
|
gptkbp:biotechnology_innovations
|
gptkb:Yes
|
|
gptkbp:biotechnology_research
|
gptkb:Yes
|
|
gptkbp:ceo
|
gptkb:Robert_A._Bradway
|
|
gptkbp:clinical_research_collaborations
|
gptkb:Yes
|
|
gptkbp:clinical_trial
|
gptkb:Yes
collaborative studies
Phase 3 trials
post-marketing studies
observational studies
real-world evidence studies
interventional studies
|
|
gptkbp:collaborations
|
gptkb:Yes
|
|
gptkbp:community_engagement
|
gptkb:Yes
gptkb:educational_institutions
gptkb:healthcare_professionals
non-profit organizations
patient advocacy
research institutions
|
|
gptkbp:community_health
|
gptkb:Yes
|
|
gptkbp:conducts_research_on
|
gptkb:David_M._Reese
|
|
gptkbp:development
|
gptkb:Yes
|
|
gptkbp:dividend_yield
|
3.1% (2023)
|
|
gptkbp:employees
|
approximately 24,000
approximately 23,000 (2020)
|
|
gptkbp:fda_approvals
|
gptkb:Yes
|
|
gptkbp:financial_support
|
gptkb:Yes
|
|
gptkbp:founded
|
gptkb:1980
|
|
gptkbp:founder
|
gptkb:George_Rathmann
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:governance
|
gptkb:Yes
|
|
gptkbp:head_of_global_commercial_operations
|
gptkb:Murdo_Gordon
|
|
gptkbp:head_of_state
|
gptkb:Yes
|
|
gptkbp:headcount
|
23,000 (2020)
|
|
gptkbp:headquarters
|
gptkb:Thousand_Oaks,_California
|
|
gptkbp:healthcare
|
gptkb:Yes
biologics
small molecules
biosimilars
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amgen Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:instruction_set
|
gptkb:Yes
|
|
gptkbp:invention
|
gptkb:Yes
|
|
gptkbp:investment
|
gptkb:Yes
|
|
gptkbp:investment_strategy
|
gptkb:Yes
|
|
gptkbp:investments_in_r&_d
|
$5.7 billion (2022)
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
$130 billion (2023)
$134.5 billion (2020)
|
|
gptkbp:marketing_strategy
|
gptkb:Yes
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:partnerships
|
gptkb:Yes
|
|
gptkbp:philanthropy
|
gptkb:Yes
|
|
gptkbp:products
|
gptkb:Enbrel
gptkb:Repatha
gptkb:Prolia
gptkb:Neulasta
Erythropoietin
|
|
gptkbp:provides_guidance_on
|
gptkb:Yes
|
|
gptkbp:publications
|
gptkb:Yes
|
|
gptkbp:regulatory_compliance
|
gptkb:Yes
|
|
gptkbp:research
|
gptkb:Yes
|
|
gptkbp:research_areas
|
gptkb:Yes
|
|
gptkbp:research_focus
|
gptkb:disease
gptkb:Cardiology
gptkb:Oncology
oncology
hematology
inflammation
neuroscience
bone health
cardiovascular diseases
nephrology
|
|
gptkbp:revenue
|
$25.42 billion (2020)
$25.42 billion (2022)
|
|
gptkbp:stock_buybacks
|
gptkb:Yes
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:AMGN
|
|
gptkbp:subsidiary
|
gptkb:KAI_Pharmaceuticals
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:supply_chain
|
gptkb:Yes
|
|
gptkbp:sustainability_initiatives
|
gptkb:administration
gptkb:Yes
employee engagement
social responsibility
community investment
environmental responsibility
|
|
gptkbp:team
|
gptkb:Yes
|
|
gptkbp:therapeutic_innovations
|
gptkb:Yes
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.amgen.com
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ
gptkb:NYSE
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|